Immunotherapy in Women’s Cancers
CME Dinner Symposium
Earn 2.0 CME Credits
Friday, May 31
Registration & Dinner:
6:30PM-7:00PM
Program:
7:00PM-9:00PM
Hilton Chicago
International Ballroom South
(Second Level)
720 S Michigan Ave
Chicago, IL 60605

Overview:

Although cervical and endometrial cancers are associated with high rates of positive clinical outcomes when detected early enough, many cases are not detected until they have reached an advanced stage. The management of patients with advanced/metastatic disease remains an important clinical challenge. Pursuit of treatment options that may help to improve clinical efficacy and limit treatment-associated adverse events is an active area of investigation, with several options showing promise in recent studies. An understanding of the mechanisms underlying the development of these diseases has helped to inform new approaches to clinical management, which may improve outcomes for your patients. The optimal utilization of deficient mismatch repair/microsatellite instability assessment and other molecular testing may also improve the integration of new treatment options into clinical practice. Keeping up with these advancements can be a challenging goal for busy clinicians, as can development of a thorough understanding of potential applications of new data from trials evaluating therapeutic approaches for advanced cervical and endometrial cancers.

Program Chair:

Bradley J. Monk, MD, FACS, FACOG
Professor
Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine
Phoenix Creighton University School of Medicine at St. Joseph’s Hospital
Medical Director
US Oncology Research Network - Gynecologic Program
Phoenix, AZ

This activity is supported by an educational grant from Merck & Co., Inc.
Medical Crossfire® How to Use Liquid Biopsies in Oncology Care
CME Dinner Symposium
Earn 2.0 CME Credits
Friday, May 31
Registration & Dinner:
6:30PM-7:00PM
Program:
7:00PM-9:00PM
Hilton Chicago
International Ballroom North
(Second Level)
720 S Michigan Ave
Chicago, IL 60605

Overview:

The remarkable advances in care for patients with cancer go beyond the development of new agents, but also includes improved techniques to diagnose and characterize patients. While tissue-based biopsies still play an integral role in the diagnosis of multiple types of cancers, the development of less invasive, plasma-based biopsy techniques allows for a safer and more rapid approach to interrogate a patient’s disease. Furthermore, liquid biopsies raise the possibility of supplementing current approaches to response assessment in patients with solid tumors. However, the interpretation of molecular tests requires a new framework in order to best apply the results to patient care. This accelerated pace of clinical advancements for the diagnosis and treatment of patients presents a challenge for you to stay current and arm yourself with the clinical knowledge and insight necessary to optimize safety and efficacy outcomes. This cutting-edge symposium will bring together both experts in liquid biopsies and internationally recognized specialists in lung, breast, and gastrointestinal cancers to provide you with the knowledge and confidence to bring state-of-the-art techniques to your practice.

Program Chair:

Benjamin P. Levy, MD
Associate Professor, Johns Hopkins School of Medicine
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
Washington, DC

This activity is supported by an educational grant from AstraZeneca and Foundation Medicine, Inc.
Show Me the Data™: AML
CME Dinner Symposium
Earn 2.0 CME Credits
Friday, May 31
Registration & Dinner:
6:30PM-7:00PM
Program:
7:00PM-9:00PM
Hyatt Regency Chicago
Columbus Ballroom A-F
(Gold Level; East Tower)
151 E Wacker Dr
Chicago, IL 60601

Overview:

This Show Me the Data™ program will cover key clinical decision points in the management of acute myeloid leukemia (AML), focusing on the frontline setting. With many advances in AML, understanding the role of recently approved strategies, such as BCL2 inhibition, IDH1/2 inhibition, and FLT3 inhibition is crucial in implementing modern therapies, both for fit patients who may be candidates for intensive chemotherapy, and for less-fit patients who may not be able to tolerate traditional treatment regimens. Integrating currently available treatments and looking toward the future will enable participants in this program to update their practice patterns through a case-based program with comprehensive data supporting each clinical decision.

Program Chair:

Naval G. Daver, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

This activity is supported by educational grants from AbbVie, Inc., Jazz Pharmaceuticals, Inc., and Takeda Oncology.
Advanced RCC Tumor Board
CME Dinner Symposium
Earn 2.0 CME Credits
Saturday, June 1
Registration & Dinner:
6:30PM-7:00PM
Program:
7:00PM-9:00PM
Hilton Chicago
International Ballroom North
(Second Level)
720 S Michigan Ave
Chicago, IL 60605

Overview:

Leveraging Evolving Data Sets to Inform Treatment Decision-Making in Advanced RCC: An Expert Tumor Board Discussion is a live symposium that will be held adjunct to the 2019 ASCO annual meeting in Chicago. This activity will bring together internationally renowned experts in the treatment of patients with advanced renal cell carcinoma (RCC). Please join this esteemed faculty for an in-depth discussion on the clinical impact of recent and emerging trial data for monotherapies and combination approaches in RCC using a “real-world” tumor board format. A series of tightly integrated case presentations will illuminate RCC treatment decisions related to sequencing and switching based on patient and disease characteristics. Adverse events and their management will be a part of the discussion. Additionally, future directions in the field will be addressed and considered in the context of how recent developments and highly anticipated trials may soon shape future patient care. Don't miss this exciting opportunity to improve your practice!

Program Chair:

Robert A. Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Director, Division of Hematology Oncology
Deputy Director
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA

This activity is supported by educational grants from Exelixis, Inc. and Merck & Co., Inc.
I/O and PARP in Ovarian Cancer
CME Dinner Symposium
Earn 2.0 CME Credits
Saturday, June 1
Registration & Dinner:
6:30PM-7:00PM
Program:
7:00PM-9:00PM
Hyatt Regency Chicago
Regency Ballroom C-D
(Gold Level; West Tower)
151 E Wacker Dr
Chicago, IL 60601

Overview:

This symposium will feature a panel of experts in the management of ovarian cancer who will present and assess the latest data on PARP inhibition and several other classes of therapy that are being explored in the field. The faculty will discuss clinical implications of the data for contemporary practice in a case-based format. During this case-based activity, clinical scenarios will be presented that explore nuances of patient care along the disease continuum. Consideration and attention to best practices for selection of treatment and maintenance approaches in multiple lines of therapy will be broached, as well as strategies for mitigation of predictable treatment-associated adverse events. Future directions in the treatment of ovarian cancer will also be addressed.

Program Chair:

Robert L. Coleman, MD, FACOG, FACS
Professor and Executive Director, Cancer Network Research
Ann Rife Cox Chair in Gynecology
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

This activity is supported by educational grants from AstraZeneca, Merck & Co., Inc., and TESARO.
Challenging Cases in EGFR+ NSCLC
CME Dinner Symposium
Earn 2.0 CME Credits
Saturday, June 1
Registration & Dinner:
6:30PM-7:00PM
Program:
7:00PM-9:00PM
Hyatt Regency Chicago
Regency Ballroom A-B
(Gold Level; West Tower)
151 E Wacker Dr
Chicago, IL 60601

Overview:

This activity will bring together internationally renowned experts in the treatment of patients with non–small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR) gene. Given that there are now many choices and decision points in the treatment of these patients, this program will seek to improve your ability to leverage appropriate data sets in your clinical practice. Testing and choosing therapy along the disease continuum will be discussed, along with strategies to manage patients with brain metastases. Adverse event management and future directions in the field will also be addressed. Throughout the program, audience participation will be integrated to encourage interaction with faculty and engagement with the content.

Program Chair:

Mark G. Kris, MD
Attending, Thoracic Oncology Service
William and Joy Ruane
Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

This activity is supported by an educational grant from AstraZeneca.
Melanoma Tumor Board
CME Dinner Symposium
Earn 2.0 CME Credits
Saturday, June 1
Registration & Dinner:
6:30PM-7:00PM
Program:
7:00PM-9:00PM
Hilton Chicago
International Ballroom South
(Second Level)
720 S Michigan Ave
Chicago, IL 60605

Overview:

The management of melanoma has shifted in recent years with improved understanding of signaling pathways and resistance mechanisms underlying the pathogenesis of metastatic melanoma, which have led to advances in the development of targeted therapies. These new approaches have allowed physicians the ability to target previously unreachable treatment goals to improve patient outcomes. Novel treatment strategies for advanced melanoma raise challenging questions, and uncertainty regarding the best strategies for integrating new treatments into current treatment paradigms often arise, in addition to concerns for the proactive management of treatment-related side effects. The ability to evaluate efficacy of new therapies, manage treatment-associated adverse events, and implement biomarkers for selecting therapy is critical for making informed decisions and optimizing patient care.

The Melanoma Tumor Board: Matching Treatment to Patient will bring together renowned international experts in melanoma treatment and clinical research to assess the clinical impact of recent and emerging trial data in melanoma. This activity will involve a series of case presentations integrating clinical trial data and will highlight melanoma treatment decisions related to current front-line and beyond therapies, treatment-related adverse events, and the impact of recent developments in the care of melanoma. Audience participation will be integrated throughout the program to encourage interaction with faculty and engagement with content.

Program Chair:

Jeffrey S. Weber, MD, PhD
Deputy Director
Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Langone Medical Center
New York, NY

This activity is supported by an educational grant from Merck & Co., Inc.
Advanced NSCLC Tumor Board
CME Dinner Symposium
Earn 2.0 CME Credits
Sunday, June 2
Registration & Dinner:
6:30PM-7:00PM
Program:
7:00PM-9:00PM
Hilton Chicago
International Ballroom North
(Second Level)
720 S. Michigan Ave.
Chicago, IL 60605

Overview:

This live CME program presented at the American Society of Clinical Oncology Annual Meeting describes current and emerging strategies for the management of patients with EGFR-mutated and ALK-mutated forms of non–small cell lung cancer (NSCLC). Appropriate strategies for identification of EGFR and ALK mutations will be explored in this program, including current strategies for the most effective use of targeted therapies. Appropriate sequencing of agents, including in patients with the ALK mutation variant T790M, will be discussed, as well as best practices for management of patients who develop resistance to initial therapy. Strategies for patient selection based on phenotypic characteristics, clinical trials for combination therapy of tyrosine kinase inhibitors and immunotherapy, the relative efficacy of agents in patients with brain metastases, and the latest updates from clinical trials in NSCLC will be examined in detail through both didactic presentations and case-based, tumor board multi-faculty discussions.

Program Chair:

David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA

This activity is supported by an educational grant from Takeda Oncology.
Navigating Pancreatic Cancer
CME Dinner Symposium
Earn 2.0 CME Credits
Sunday, June 2
Registration & Dinner:
6:30PM-7:00PM
Program:
7:00PM-9:00PM
Hilton Chicago
International Ballroom South
(Second Level)
720 S Michigan Ave
Chicago, IL 60605

Overview:

Pancreatic adenocarcinoma remains among the most challenging malignancies to treat, but ongoing clinical research is continually emerging with the potential to improve outcomes and patient care. In this interactive, case-based satellite symposium, Navigating Treatment Sequencing in Pancreatic Cancer: Experts Paving the Road Towards Patient-Centric Care, the latest cutting-edge data will be presented within a framework of patient cases. The panel of experts in pancreatic cancer treatment and management will discuss evidence-based, guideline-recommended therapies and potential drug sequencing; the differential clinical profile of available treatments, including adverse event as well as pharmacodynamic and pharmacokinetic profiles; and the latest clinical trial developments in the evolving treatment landscape for pancreatic cancer. During this program, interactive questions interspersed throughout case presentations will give you the opportunity to identify and reflect on the optimal management of pancreatic cancer, and how to integrate emerging options into plans of care for your patients.

Program Chair:

Eileen M. O'Reilly, MD
Associate Director
David M. Rubenstein Center for Pancreatic Cancer Research
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

This activity is supported by an educational grant from Ipsen Biopharmaceuticals, Inc.